

2/7/1 (Item 1 from file: 351)
DIALOG(R)File 351:Derwent WPI
(c) 2004 Thomson Derwent. All rts. reserv.

007572238

WPI Acc No: 1988-206170/**198830**

Monoclonal antibodies against human alpha interferon prodn. - by fusing
spleen cells from immunised mice with myeloma cells, selection, determine
specificity then growing in vitro or in vivo

Patent Assignee: AKAD WISSENSCHAFTEN DDR (DEAK)

Inventor: FRITZKE H; MUNSTER H; TONEW E; TONEW M; WISNIEWSKI H G;
WOLLWEBER

L; WONDRACZEK R

Number of Countries: 001 Number of Patents: 001

Patent Family:

Patent No	Kind	Date	Applicat No	Kind	Date	Week
DD 254593	A	19880302	DD 297612	A	19861215	198830 B

Priority Applications (No Type Date): DD 297612 A 19861215

Patent Details:

Patent No	Kind	Lan Pg	Main IPC	Filing Notes
DD 254593	A	3		

Abstract (Basic): DD 254593 A

Prod. of monoclonal antibodies (MAb) against human alpha
interferon (I) comprises immunising BALB/c mice with (I), fusing spleen
cells with myeloma cells; selection of the resulting hybridomas and
detecting their antigen determinant specificity by a solid-phase
bioassay. The selected hybridoma clones, H/B61D3 and H/C61D2, are then
cultured or transplanted in mice, pref. BALB/c x NMRI or NMRI x BALB/c
hybrids, and MAb isolated either from the culture supernatant or from
the ascites fluid.

USE/ADVANTAGE - MAb are used in immunochemical determ. of (I) and
for affinity-chromatographic purificn. This method gives a high yield
of hybridomas and makes possible rapid and reliable recovery of stable
hybrid clones, which saves expensive cell culture media. Both (I)
subtypes are recognised by MAb so that immunoassay procedures require
labelling of only one antibody.

0/0

Derwent Class: B04; D16

International Patent Class (Additional): C12N-005/02